SecBot SecBot
6-K ·Filed Nov 4, 2026

SNN

SMITH & NEPHEW PLC
BEARISH
Impact 6/10
Horizonweeks Processed12d 16h ago SEC0001104659-26-122324
6-K: Earnings release
Actionable Insight ▼ Bearish

The guidance cut and weak US Orthopaedics performance are the primary negatives. Watch Q4 results for further deterioration in US Hips/Knees and any update on Orthopaedics strategic review (potential spin-off or sale). The strong Sports Medicine & ENT momentum provides a partial offset but is insufficient to reverse the bearish read.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$32.46
T+0 close · Nov 4, 2026 · via day close
Latest settled
−4.37%
T+5 · $31.04
Vs SPY
−3.46%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 4 $32.46entry
  2. T+1 · 12d ago −1.39%α +3.02% · $32.01
  3. T+5 · 6d ago −4.37%α −3.46% · $31.04
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Smith+Nephew reported Q3 2026 revenue of $1,551M (+3.4% YoY underlying), missing consensus of $1.56B. Full-year underlying revenue growth guidance was lowered to ~3% from ~4%, and trading profit guidance to ~4% growth (from ~8%), with trading profit now expected at ~$1.25B. The guidance cut reflects slower-than-expected US Orthopaedics (Hips and Knees) performance, partially offset by strong Sports Medicine & ENT growth.

Key Financial Metrics

Revenue
$1.6B
est $1.6B · -0.6% · +3.4% YoY
Guidance
around 3% underlying growth (previously around 4%)
lowered
Free Cash Flow
$750.0M

Key Facts

  • Q3 revenue $1,551M, +3.4% YoY underlying (consensus $1.56B)
  • Full-year underlying revenue growth guidance lowered to ~3% from ~4%
  • Trading profit guidance cut to ~4% growth (from ~8%), now ~$1.25B
  • Free cash flow guidance reduced to ~$750M from ~$800M
  • US Knee Implants revenue declined -7.3% YoY; US Hip Implants -1.0%
  • Sports Medicine & ENT revenue +7.9% underlying; Joint Repair +11.2%
  • Advanced Wound Bioactives revenue -8.8% underlying on reimbursement changes
  • Board exploring strategic options for Orthopaedics; J&J Depuy Synthes discussions ended
  • $500M buyback on track, $250M completed by end of Q3

Financial Impact

Guidance reduction implies ~$50M lower trading profit and ~$50M lower FCF vs prior targets; revenue growth outlook cut by ~1 percentage point

revenuetrading profitfree cash flowROIC

Segment Breakdown

SegmentRevenueGrowth
Sports Medicine & ENT$507.0M+7.9%
Advanced Wound Management$454.0M-0.2%
Orthopaedics$590.0M+2.5%

Risk Factors

  • Further weakness in US Orthopaedics (Hips and Knees) could drive additional guidance cuts
  • Advanced Wound Bioactives headwind from reimbursement changes may persist longer than guided
  • Orthopaedics strategic review may result in a value-destructive outcome or no deal
  • China VBP implementation in Arthroscopic Enabling Technologies and ENT could pressure growth

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
38% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-122324
Document: 0001104659-26-122324-index-headers.html0001104659-26-122324
Document: 0001104659-26-122324-index.html0001104659-26-122324
Document: 0001104659-26-122324.txt0001104659-26-122324
Earnings Context (Synthetic; results releases only)0001104659-26-122324

Track record

42 reports on SNN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
  2. Nov 4, 202612d ago 6-K Bearish 6/10 No price data
  3. Nov 4, 202612d ago 6-K Bearish 6/10 Viewing Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
  4. Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
  5. Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
  6. Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
  7. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  8. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  9. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
  10. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
Showing 10 of 42

US Market Status

Market Closed · Opens Wed (10h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026